Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

e II trial and another milestone upon the dosing of the first patient in a Phase III trial for any use of the drug.

Myriad also reported data from two completed Phase 1 clinical trials of Azixa in a total of 66 patients, one in patients with refractory solid tumors that may also have had brain metastases and the other in patients with known brain metastases. The trials were designed to explore the safety and pharmacokinetics of Azixa and to find the maximum tolerated dose of the compound. Myriad reported that in the Phase 1 studies, Azixa appeared to have a biological effect on patients' metastases from many different primary tumors, including non-small-cell lung cancer, which is consistent with the mechanism of the drug candidate.

Azixa is one of two compounds in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with advanced, solid tumors and lymphomas, is currently in Phase I clinical development by EpiCept. In July 2007, EpiCept announced the acceleration of the Phase I clinical trial, with results expected later this year. EpiCept expects to initiate a second Phase I efficacy trial for EPC2407 as a combination therapy in patients with well vascularized solid tumors and intends to choose multiple tumor targets for the compound's Phase II trials as the clinical profile from the ongoing monotherapy trial emerges.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in cancer cells, thereby checking, and perhaps reversing, the improper ce
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...rmaceuticals (SPI) has filed,an Investigational Ne...esting of a proprietary formulation of ebselen for...ss or ototoxicity. The oral capsule,containing ebs...ung cancer,and head and neck cancer patients recei...econd development program for SPI to enter clinica...
(Date:7/23/2008)...ma Inc., a company developing,breakthrough molecul...aphy,(PET) market, announced positive Phase I resu...r for myocardial perfusion imaging. BFPET is,Fluor...e Phase I clinical,development., BFPET is a PET i... the,heart (myocardial perfusion). Myocardial perf...
(Date:7/23/2008)...ode BioPharmaceutics, Inc.,an emerging biopharmac...results demonstrating the utility of their lead dr...hronic blood disorder paroxysmal nocturnal,hemoglo...ted at the XXII,International Complement Workshop ...nly treatment currently available for PNH patients...
(Date:7/23/2008)...Protein Therapeutics that Modulate Alter...ass., July 23 /- Taligen Therapeutics... growth plan with the,appointment of Abbie Celnike...lishment of its headquarters in Cambridge, Mass. D...under of the company who remains president., Unde...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 1Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 2Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 3Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 4Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti Cancer Co 672 5Threepeat for HealthPus 21 4676 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 1NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 2NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock 1519 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 1Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 2Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 3Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 4Everett Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca 4673 5
...2007 - Elixir,Pharmaceuticals, Inc., announced tod...he ability of Glufast(R) (mitiglinide calcium,hydr...ormin, to,manage glucose surges before and after m... for the American Diabetes,Association 67th Annual... is an insulin secretagogue that lowers postprandi...
...- CytRx Corporation,(NASDAQ:CYTR), a biopharmaceut...cialization of human therapeutics, today,reported ...y,announced double-blind, placebo-controlled, risi...ers with its drug candidate,arimoclomol. CytRx bel...se of arimoclomol in future clinical trials, inclu...
Other Medicine Technology:Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 2CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 3CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 4CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS 5
(Date:7/25/2008)...S, July 25 /PRNewswire/ -- BeaconEquity.com announ...ing news today., Investors can view all of the da...aconEquity.com/m , Today,s Trade Alerts include: ...Brook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaM...R ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis I...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begins ... -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), a ...d today that its subsidiary has commenced commerci...ules USP product in the 40mg,strength from its Dav...,with the launch, Watson has 180 days of marketing...
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...can be toughest for those trying to drop pounds, s...y News) -- Anyone who has avoided Monday morning w...e not a dieter,s friend. , Now, researchers hav...t weekends being their undoing: Most people do eat...lose weight. , "Weekend indulgences can wreak h...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
...pective study conducted by researchers from the Ge...rfs in ancient Egypt had received their much-deser...emains and other art forms demonstrated that dwarf...ical deformity. Infact, ancient Egyptians even wo...
...an woman was ecstatic that she and her daughter tr...mas in an intensive care unit // . Mariam Ameh’s ...ell after journeying to Cleveland's Rainbow Babies...e doctors removed a brain tumor the size of a grap...
...r Lloyd Johnston of the University of Michigan in ...e was a decrease in smoking in these students but ...ous painkillers // . The researchers found that al...g drugs. The increase in use of painkillers may be...
...abia is gearing up to face around 2.5 million Hajj...reening when they enter Saudi Arabia to all the Ha...ion//. World wide the threat of pandemic bird flu ...ns and spread of the virus is high in mass gatheri...
Other Medicine News:Health News:Respecting Dwarfs- A Lesson To Be Learnt From Ancient Egyptians 2Health News:Nigerian girl recovering well after removal of brain tumor 2
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: